ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
港股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
药捷安康-B
26.950
+0.650
2.47%
手动刷新
成交量:
108.32万
成交额:
2,904.18万
市值:
106.96亿
市盈率:
-34.19
高:
28.500
开:
26.400
低:
25.500
收:
26.300
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
药捷安康-B
交易所:
SEHK
成立时间:
2014
员工人数:
- -
公司地址:
Building 9, Accelerator Phase 2,3rd Floor,Biotech and Pharmaceutical Valley,Jiangbei New Area,Nanjing,Jiangsu Province,China
官网:
http://www.transtherabio.com
邮编:
210032
电话:
86 25 5821 6200
传真:
- -
简介:
药捷安康(南京)科技股份有限公司是一家从事生物制药的中国公司,主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的 MTK 抑制剂,适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括 TT-00973(针对 AXL)、TT-01488(用于血液系统恶性肿瘤)、TT-01688(用于炎症性疾病)和 TT-00920(用于慢性心力衰竭)。这些产品能够对多种癌症类型(包括前列腺癌、肝癌、乳腺癌和 BTC)产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和 Pan-FGFR 实体瘤。
董事
名称
职位
吴永谦
董事长,执行董事,战略委员会主席,提名委员会委员
吴笛
执行董事
徐海音
独立非执行董事,战略委员会委员,薪酬与考核委员会委员,提名委员会主席
郑哲兰
独立非执行董事,薪酬与考核委员会主席,提名委员会委员,审核委员会委员
李书湃
独立非执行董事,审核委员会主席
贾中新
非执行董事,战略委员会委员,薪酬与考核委员会委员,审核委员会委员
易华
非执行董事
赵卫丽
监事会主席,职工代表监事
梅江华
股东代表监事
庞亚京
股东代表监事
股东
名称
职位
吴永谦
首席执行官
吴笛
副总裁,财务负责人
冯洁
董事会秘书,联席公司秘书
黄荻
联席公司秘书
樊菁
首席医疗官
崔松喜
运营副总裁
彭鹏
项目管理副总裁
盛泽娟
生物副总裁
孙彩霞
临床执行总监
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02617/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":26.95,"timestamp":1751007980001,"preClose":26.3,"halted":0,"volume":1083200,"delay":0,"floatShares":301666673,"shares":396897633,"eps":-0.7885211318136147,"marketStatus":"交易中","change":0.65,"latestTime":"06-27 15:06:31","open":26.4,"high":28.5,"low":25.5,"amount":29041775,"amplitude":0.114068,"askPrice":27.1,"askSize":1000,"bidPrice":26.85,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.7885211318136147,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1751011800000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":26.3,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"volumeRatio":0.37514,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":301666673,"roa":"-24.05%","roe":"-41.98%","lyrEps":-0.788306,"volumeRatio":0.37514,"shares":396897633,"dividePrice":0,"high":28.5,"amplitude":0.114068,"preClose":26.3,"low":25.5,"week52Low":20.2,"pbRate":"18.60","week52High":28.5,"institutionHeld":0,"latestPrice":26.95,"committee":-0.333333,"eps":-0.7883064821652851,"divideRate":0,"volume":1083200,"delay":0,"ttmEps":-0.7883064821652851,"open":26.4,"prevYearClose":13.15,"prevWeekClose":13.15,"prevMonthClose":13.15,"prevQuarterClose":13.15,"fiveDayClose":13.15,"twentyDayClose":13.15,"sixtyDayClose":13.15},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":404671245,"yearFounded":2014,"address":"Building 9, Accelerator Phase 2,3rd Floor,Biotech and Pharmaceutical Valley,Jiangbei New Area,Nanjing,Jiangsu Province,China","zipCode":"210032","officePhone":"86 25 5821 6200"},"stockCompanyDetail":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":1},{"period":"ytd","weight":1}],"compareEarnings":[{"period":"1week","weight":0.0468},{"period":"1month","weight":0.0403},{"period":"3month","weight":0.0384},{"period":"6month","weight":0.2108},{"period":"1year","weight":0.3447},{"period":"ytd","weight":0.2126}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康(南京)科技股份有限公司是一家从事生物制药的中国公司,主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的 MTK 抑制剂,适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括 TT-00973(针对 AXL)、TT-01488(用于血液系统恶性肿瘤)、TT-01688(用于炎症性疾病)和 TT-00920(用于慢性心力衰竭)。这些产品能够对多种癌症类型(包括前列腺癌、肝癌、乳腺癌和 BTC)产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和 Pan-FGFR 实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":{"directors":[{"name":"吴永谦","position":"董事长,执行董事,战略委员会主席,提名委员会委员"},{"name":"吴笛","position":"执行董事"},{"name":"徐海音","position":"独立非执行董事,战略委员会委员,薪酬与考核委员会委员,提名委员会主席"},{"name":"郑哲兰","position":"独立非执行董事,薪酬与考核委员会主席,提名委员会委员,审核委员会委员"},{"name":"李书湃","position":"独立非执行董事,审核委员会主席"},{"name":"贾中新","position":"非执行董事,战略委员会委员,薪酬与考核委员会委员,审核委员会委员"},{"name":"易华","position":"非执行董事"},{"name":"赵卫丽","position":"监事会主席,职工代表监事"},{"name":"梅江华","position":"股东代表监事"},{"name":"庞亚京","position":"股东代表监事"}],"executives":[{"name":"吴永谦","position":"首席执行官"},{"name":"吴笛","position":"副总裁,财务负责人"},{"name":"冯洁","position":"董事会秘书,联席公司秘书"},{"name":"黄荻","position":"联席公司秘书"},{"name":"樊菁","position":"首席医疗官"},{"name":"崔松喜","position":"运营副总裁"},{"name":"彭鹏","position":"项目管理副总裁"},{"name":"盛泽娟","position":"生物副总裁"},{"name":"孙彩霞","position":"临床执行总监"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2025-06-26","current":-34.709071,"percent":0,"low":-34.709071,"twenty":-33.367742,"median":-31.953986,"eighty":-28.333869,"high":-17.403134,"avg":-29.633031,"sd":6.234327,"marketCap":10438407747},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-26","current":-34.709071,"twenty":-33.367742,"median":-31.953986,"eighty":-28.333869,"marketCap":10438407747}],"updateTime":1751006277901}}}